ArticlePloS one2016
"When Treatment Is More Challenging than the Disease": A Qualitative Study of MDR-TB Patient Retention.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Effectiveness and Safety of Bedaquiline-Containing Modified Shorter Regimens for Multidrug- or Rifampicin-Resistant Tuberculosis: A Single-Arm Meta-Analysis.Pathogens (Basel, Switzerland) · 2026Pooled it
- Patient adherence to tuberculosis treatment in the Indian subcontinent: systematic review and meta-synthesis of qualitative research.BMJ open · 2023Pooled it
- Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment.PloS one · 2023Pooled it
- Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis.BMC medicine · 2018Pooled it
- Trial
- DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.PloS one · 2017Trial
- Article
- Person-centred care for people with tuberculosis-associated comorbidities: a multi-country qualitative study.BMJ open · 2025Article
- Article
- Perceptions of shorter radical cure Plasmodium vivax treatment regimens and their implementation: a qualitative study among stakeholders in Cambodia.Malaria journal · 2025Article
- Article
- Treatment completion of drug-resistant tuberculosis in Ethiopia: A perspective from healthcare users.PLOS global public health · 2025Article
- TB stigma in India: A narrative review of types of stigma, gender differences, and potential interventions.PLOS global public health · 2025Review
- Management of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis.The Lancet regional health. Southeast Asia · 2024Article
- Why do patients with DR-TB do not complete their treatment? Findings of a qualitative study from Pakistan.BMJ open respiratory research · 2024Article
- South African adolescents' lived experiences of acquired hearing loss following multidrug-resistant tuberculosis treatment.Frontiers in rehabilitation sciences · 2024Article
- Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study.BMJ open · 2023Article
- Exploring Knowledge about Fang Traditional Medicine: An Informal Health Seeking Behaviour for Medical or Cultural Afflictions in Equatorial Guinea.Healthcare (Basel, Switzerland) · 2023Article
- Coping with drug resistant tuberculosis alongside COVID-19 and other stressors in Zimbabwe: a qualitative study.medRxiv : the preprint server for health sciences · 2023Article
- Predictors of multidrug-resistant tuberculosis in a teaching hospital in Ghana: A case-control study.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne-fifth of the patients on multidrug-resistant tuberculosis treatment at the Drug-Resistant-TB (DR-TB) Site in Gujarat are lost-to-follow-up(LFU).
objectiveTo understand patients' and providers' perspectives on reasons for LFU and their suggestions to improve retention-in-care.
designQualitative study conducted between December 2013-March 2014, including in-depth interviews with LFU patients and DOT-providers, and a focus group discussion with DR-TB site supervisors. A thematic-network analysis approach was utilised.
resultsThree sub-themes emerged: (i) Struggle with prolonged treatment; (ii) Strive against stigma and toward support; (iii) Divergent perceptions and practices. Daily injections, pill burden, DOT, migratory work, social problems, prior TB treatment, and adverse drugs effects were reported as major barriers to treatment adherence and retention-in-care by patients and providers. Some providers felt that despite their best efforts, LFU patients remain. Patient movements between private practitioners and traditional healers further influenced LFU.
conclusionThe study points to a need for repeated patient counselling and education, improved co-ordination between various tiers of providers engaged in DR-TB care, collaboration between the public, private and traditional practitioners, and promotion of social and economic support to help patients adhere to MDR-TB treatment and avoid LFU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.